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Introduction: Thymic carcinoma is a rare malignancy often presenting at an advanced 
stage. Radiation therapy and chemotherapy are often the only treatment options avail-
able to physicians.
Methods: A 70-year-old man presented with an unresectable stage III thymic tumor and 
was treated with 45 Gy in 25 fractions followed by a boost of 21.6 Gy in 12 fractions. 
He was also treated with bortezomib for multiple myeloma unrelated to his primary 
malignancy.
Results: The patient made a full recovery following the radiation regimen and remained 
disease free 4 years after the treatment.
Conclusion: Exclusive treatment with intensity-modulated radiation therapy provides a 
viable treatment option for patients presenting with advanced stage thymic carcinoma.
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INtRoDUCtIoN
Thymoma and thymic carcinoma are primary tumors of the thymus that arise in the anterior 
mediastinum. Thymomas are histologically benign and are capable of behaving in a malignant 
fashion by extending into the thymic capsule (1). On the one hand, thymomas have a reported 
incidence of 1.5 cases per million (2). On the other hand, thymic carcinomas are even more rare 
in the population and are histologically malignant. They tend to demonstrate a more aggressive 
behavior by invading the thymic capsule early on. Given the rarity of thymic carcinoma, studies of 
thymic carcinoma are predominantly retrospective case reports spanning a number of decades at a 
single institution. The risk factors for thymic carcinoma remain unknown; however, thymic masses 
generally occur in adults (3). Treatment options include surgical resection, chemotherapy, and/or 
radiotherapy with complete surgical resection having the most favorable outcome (4–6). Tumor 
grade, stage, and resectability are essential prognostic factors (7).
Surgical resection of thymic carcinoma is not always an option as the majority of thymic tumors 
present at an advanced stage. Other medical comorbidities may also play a role in whether a patient 
undergoes surgery. In these circumstances, chemotherapy and/or radiation therapy can be used. 
We include a case of a 70-year-old man diagnosed with stage III thymic carcinoma managed with 
definitive radiation therapy alone and discuss literature as it relates to radiation as a curative modality 
for this disease.
FIGURe 2 | pet scan prior to radiation.
FIGURe 1 | Ct scan prior to radiation.
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Case pReseNtatIoN
A 70-year-old man presented to his primary physician with 
dysphagia that progressed to upper chest and back-pressure. 
The patient underwent imaging, and a large anterior mediastinal 
mass was detected on computed tomography (CT). The mass was 
biopsied, and the patient was subsequently referred for further 
work-up. Pathology of the tumor was reviewed and confirmed 
to be poorly differentiated squamous cell carcinoma. The tumor 
histology was most consistent with thymic origin; however, 
metastasis of other sources, such as lung, could not be ruled 
out. A repeat CT scan (Figure 1) showed a necrotic mediastinal 
mass with local sternal invasion. An initial positron emission 
tomography (PET) scan (Figure  2) showed a hypermetabolic 
anterior mediastinal mass without evidence of regional or distant 
metastases. The anterior mediastinal location made the mass 
most likely of thymic source. Upon presentation, the patient 
denied any hemoptysis, voice changes, fatigue, weakness, vision 
changes, headaches, nausea, or vomiting. The patient underwent 
surgery for removal of the tumor. During the operation, the 
tumor was found to invade the sternum and bilaterally encase 
both the phrenic nerves. In attempts to see if the phrenic nerves 
could be freed without injury, the pericardial sac was opened 
and the right phrenic nerve was followed. Based on the extent of 
tumor invasion of the right phrenic nerve, the surgeon concluded 
that there was no safe way to free both the phrenic nerves without 
injury, and the tumor was concluded to be unresectable.
The patient was referred to oncology and radiation oncology for 
other definitive therapy options. The patient was not considered a 
candidate for cisplatin therapy due to a rising protein–creatinine 
ratio at the time of presentation. A biopsy obtained for further 
work-up of his poor kidney function showed lambda light chain 
deposits consistent with multiple myeloma. After consultation 
with radiation oncology, intensity-modulated radiation therapy 
(IMRT) was recommended for definitive management of his 
thymic carcinoma. The plan was designed to deliver volumes 
based on the image data seen in Figure 3. A dose of 45 Gy in 
25 fractions (red line) was prescribed to cover the thoracotomy 
operative bed, mediastinum, and level VI lymph node region of 
the low neck. A boost plan of 21.6 Gy in 12 fractions was designed 
to cover the gross tumor (blue color wash), bringing the total dose 
to the gross tumor to 66.6 Gy (yellow line). IMRT resulted in a 
lower dose to the spinal cord and heart while maintaining target 
coverage compared to a 3D-conformal technique. In addition, the 
patient was started on a regimen of bortezomib and dexametha-
sone for treatment of multiple myeloma during this time.
Overall, the patient tolerated the treatment well and did not 
experience any significant side effects other than skin irritation. 
The patient did notice gradual improvement in his dysphagia 
throughout treatment. A CT performed 1 month following the 
completion of his treatment showed a decrease in the size of his 
mediastinal mass (6.8 cm × 3.0 cm × 4.2 cm) when compared to 
the mass initial size prior to radiation (8.4 cm × 5.7 cm × 7.8 cm). 
The CT also showed no enlarged lymph nodes of the axilla or 
mediastinum and was negative for pulmonary metastases. 
Imaging revealed a new right pericardial thickening that was 
later determined to be radiation-induced inflammation. The 
patient had significant improvement in kidney function after 
completing 22 cycles of bortezomib and dexamethasone for 
his multiple myeloma. His protein–creatinine ratio normalized 
within 6 months of this treatment. A bone marrow biopsy prior 
to treatment showed 30% plasma cells and 1% plasma cells fol-
lowing treatment. He continues to stay on a maintenance dose of 
dexamethasone.
The patient was last seen in radiation oncology 4 years follow-
ing the completion of his radiation regimen. He reports that he 
is doing well and is symptom free. To date, the patient’s CT scan 
continues to show a stable small soft tissue mass in the anterior 
mediastinum with surrounding fat stranding consistent with 
radiation change.
FIGURe 3 | Radiation treatment plan.
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DIsCUssIoN
Due to the rarity of thymic carcinoma, large prospective studies 
on the therapeutic management of thymic carcinoma are limited. 
As a result, clinical management of thymic carcinoma is poorly 
defined. Radiation therapy alone for the definitive treatment of 
thymic carcinoma is not well reported as these cases are often 
grouped together with thymomas. The National Comprehensive 
Cancer Network (NCCN) recommends a radiation dose range 
of 60–70 Gy for inoperable tumors. For operable tumors under-
going adjuvant radiotherapy, the NCCN specifies 45–50 Gy for 
clear margins, 54 Gy for microscopically positive margins, and 
60  Gy for positive gross margins post resection (2). The range 
1.8–2.0 Gy is considered a conventional fractionation (2).
Using radiation therapy as a definitive treatment has been 
suggested in a number of studies. In Korst et al., 21 patients with 
thymic carcinoma and thymoma underwent neoadjuvant chemo-
radiotherapy (2 cycles of etoposide and cisplatin) and 45  Gy of 
radiotherapy. Eighteen of the 19 patients, who had reported PET 
SUVmax values, experienced a decrease in their SUVmax with the 
median change of −44.5%. The study also observed a greater tumor 
response in thymic carcinoma lesions in comparison to thymoma 
lesions. Four of the five patients who had obtained near to complete 
pathologic response were patients with thymic carcinoma (8).
Studies have suggested the benefits of radiation therapy when 
used with neoadjuvant and adjuvant therapy by making tumors 
more resectable and improving local control, respectively (9). 
Hsu et al. showed promising local control in thymic carcinoma 
tumors that underwent complete or incomplete surgical resection 
with 40–70 Gy of radiotherapy. The 5-year local control rate in 
completely and incompletely resected thymic carcinoma tumors 
plus radiotherapy was 92 and 88%, respectively. The study con-
cluded that the local control was notable; however, the average 
distant metastasis-free rate of 57% was unimpressive (10). Overall, 
the study showed the benefit of radiation therapy in incompletely 
resected tumors which is comparable to inoperable tumors. 
In the study of Liu et  al., 17 patients with unresectable thymic 
malignancies who underwent radiotherapy and/or chemotherapy 
were compared to 4 patients with unresectable thymic tumors who 
did not undergo treatment. Although the study presented a small 
cohort, it is worth noting as it is one of the few papers to show 
benefit in treatment versus no treatment in inoperable tumors (7).
The use of proton therapy has been explored in the treatment 
of mediastinal masses. Although systematic reviews suggest that 
proton therapy has not proven to be superior to photon therapy, 
more recent studies have shown the potential of less toxicity in 
lung cancer patients receiving proton therapy (11). Chang et al. 
showed that 34 patients with lung and mediastinal tumors who 
received a median of 66 Gy of intensity-modulated proton therapy 
(IMPT) had significantly lower radiation dosage to normal tissues 
(heart, lung, and esophagus), when compared to IMRT plans that 
were contoured for the same patients’ tumors (12). More clinical 
trials are needed to further explore the possible improvement in 
the side effect profile proton therapy could offer.
In this case, the patient’s thymic carcinoma has been found 
to be unresectable due to its involvement with both the phrenic 
nerves. Chemotherapy and radiation therapy were both explored 
as alternative definitive treatment options. The patient’s renal 
function made him a poor candidate for the chemotherapy regi-
men of choice, cisplatin. He was a good candidate for radiation 
therapy and successfully completed a regimen of 66.6 Gy/37 frac-
tions. It is important to note that the patient started bortezomib 
for multiple myeloma during his radiation therapy and continued 
bortezomib post-radiation. It is uncertain whether bortezomib 
played a role in the patient’s treatment outcomes. Overall, the 
reduction in the patient’s tumor size and persistent local control 
suggest that IMRT is a useful definitive treatment option for 
unresectable thymic carcinoma tumors.
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